实用肿瘤杂志2025，Vol.40Issue(2)：127-133,7.DOI:10.13267/j.cnki.syzlzz.2025.020
晚期EGFR突变肺腺癌患者中PD-L1表达对EGFR-TKI治疗疗效的影响
Effect of PD-L1 expression on efficacy of EGFR-TKI in advanced lung adenocarcinoma patients with EGFR mutations
摘要
Abstract
Objective To investigate the impact of programmed death-ligand 1(PD-L1)expression on the efficacy of epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitor(TKI)in advanced lung adenocarcinoma patients with EGFR mutations.Methods A total of 113 advanced lung adenocarcinoma patients with EGFR-sensitive mutations treated with first-line third-generation EGFR-TKI osimertinib at the Third Clinical Medical College of Xinjiang Medical University from January 2020 to December 2022 were included in this study.The expression of PD-L1 in lung adenocarcinoma tissues was detected by immunohistochemistry.Kaplan-Meier analysis was used for survival analysis.Log-rank test and Cox proportional hazards regression model were used for univariate and multivariate analy-sis to identify factors affecting the efficacy of the targeted therapy.Results The median progression free survival(PFS)was significantly different between patients with positive[tumor proportional score(TPS)≥1%]and negative(TPS<1%)PD-L1 expression(7.0 months vs 16.0 months,P<0.01).Among patients with positive PD-L1 expression,the median PFS was significantly different between those with high(TPS≥50%)and low(1%≤TPS<50%)PD-L1 expression(6.0 months vs 9.0 months,P<0.01).In patients with EGFR ex19del and 21L858R mutations,the median PFS was significantly different between those with positive and negative PD-L1 expression(EGFR ex19del:8.0 months vs 16.0 months,P<0.01;EGFR 21L858R:6.0 months vs 13.0 months,P<0.01).Multivariate analysis showed that EGFR mutation type and PD-L1 expression were factors affecting the PFS of advanced lung adenocarcinoma patients with EGFR mutations treated with first-line osimertinib(both P<0.01).Conclusions The expression of PD-L1 and EGFR mutation type can affect the PFS of advanced lung adenocarcinoma patients with EGFR mutations treated with EGFR-TKI.关键词
肺腺癌/表皮生长因子受体/程序性死亡受体配体1/靶向治疗/疗效Key words
lung adenocarcinoma/epidermal growth factor receptor/programmed death-ligand 1/targeted therapy/efficacy引用本文复制引用
陶洁,雒静,张琰..晚期EGFR突变肺腺癌患者中PD-L1表达对EGFR-TKI治疗疗效的影响[J].实用肿瘤杂志,2025,40(2):127-133,7.基金项目
新疆维吾尔自治区自然科学基金面上项目(2021D01C383) （2021D01C383）
